General Description
Comvax is a combination of Haemophilus influenzae type bconjugate and hepatitis B (recombinant). It was recentlyapproved by the Advisory Committee on ImmunizationPractices (ACIP). Each 0.5-mL dose contains 7.5 μg ofH. influenzae type b polyribosylribitol phosphate (PRP),125 μg of Neisseria meningitidis outer membrane proteincomplex (OMPC), and 5 μg of hepatitis B surface antigen(HBsAg) on an aluminum hydroxide adjuvant. TheCommittee on Infectious Diseases, the American Academyof Pediatrics, and the Advisory Academy of FamilyPhysicians recommend that all infants receive the vaccine.Three doses should be administered at ages 2, 4, and 12 to15 months. The vaccine should not be administered to infantsyounger than 6 weeks because of potential suppressionof the immune response to PRP-OMPC with subsequentdoses of Comvax TM. The series should be completed by 12to 15 months.
